Mouries O, Bonnet M
Clinique Ophtalmologique Universitaire B, UER Lyon Nord, Hôpital de la Croix Rousse.
J Fr Ophtalmol. 1992;15(11):601-4.
We conducted a clinical trial on C2F6 as a retinal tamponade in the management of retinal detachment with proliferative vitreoretinopathy. Twenty seven eyes of 27 consecutive patients were enrolled in the study. Permanent retinal reattachment was achieved in 21 eyes (78%). The anatomic success rate was 85% in eyes with grade B PVR (17/20 eyes), and 57% in eyes with grade C and D PVR (4/7 eyes). The success rate was as high as that achieved in a previous series of eyes managed with the use of C3F8 combined with the same surgical technique. C2F6 shares the advantages of C3F8 in the management of retinal detachments complicated by proliferative vitreoretinopathy. However its absorption is more rapid as compared to C3F8. This is an advantage with regard to the postoperative disadvantages of gas tamponade. Further clinical use on a larger series of patients is required to confirmed the preliminary results.
我们进行了一项临床试验，将六氟乙烷（C2F6）作为视网膜填塞剂用于治疗伴有增殖性玻璃体视网膜病变的视网膜脱离。连续27例患者的27只眼纳入本研究。21只眼（78%）实现了视网膜永久性复位。B级增殖性玻璃体视网膜病变（PVR）患者的解剖复位成功率为85%（20只眼中的17只），C级和D级PVR患者的成功率为57%（7只眼中的4只）。该成功率与先前一系列采用八氟丙烷（C3F8）联合相同手术技术治疗的患眼所达到的成功率一样高。在治疗并发增殖性玻璃体视网膜病变的视网膜脱离方面，C2F6具有C3F8的优点。然而，与C3F8相比，其吸收更快。就气体填塞的术后缺点而言，这是一个优点。需要对更多患者进行进一步的临床应用，以证实初步结果。
